CClinicalTrials.gg
CompletedNCT03047642Updated Feb 16, 2021

Validation of Promising Biomarker Assays to Assess Their Diagnostic Performance Characteristics

An observational study in Acute Febrile Illnesses, sponsored by Foundation for Innovative New Diagnostics, Switzerland. Completed at 3 sites in 3 countries. Open to participants aged 2 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-02-16.

Sponsored by Foundation for Innovative New Diagnostics, Switzerland · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
2,000
Ages
2 Years to 65 Years
Sex
All
01

Study summary

This project aims to evaluate the performance characteristics of rapid tests to differentiate bacterial from non-bacterial infection in febrile adults and children presenting at OPDs (outpatient departments) i.e.("fever triage assays") in three LMICs. The evaluation will include a different commercial biomarker combinations as well as individual biomarkers to assess their individual or combined value in the target population. Markers will be evaluated onsite in ELISA or RDT format, as appropriate. Further, this study aims to contribute to a centralized biobank of well-characterized specimens for use by IVD companies and academic institutions for the development and evaluation of emerging assays.

02

Conditions studied

  • Acute Febrile Illnesses

Keywords

  • biomarker
  • low and middle income countries
  • fever
  • antimicrobial resistance
  • diagnostic
03

Who can participate

Ages eligible
2 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Any non-severely ill subject presenting with acute fever defined as: temperature of more than 38°C at initial evaluation of less than 7 days of symptoms at presentation.

For recruitment purposes, subjects will be classified into two groups:

  • Children 2-17 years of age
  • Adults 18-65 years of age

Eligibility criteria

Inclusion Criteria:

Any non-severely ill subject presenting with acute fever defined as: temperature of more than 38°C at initial evaluation of less than 7 days of symptoms at presentation.

Inclusion criteria:

  • Children 2-17 years of age
  • Adults 18-65 years of age
  • Signed written informed consent for study participation. For recruitment purposes, subjects will be classified into two groups, children and adults. For children, age >2 years is the minimum cut-off, based on the amount of blood volume to be obtained in the study. WHO guidelines for allowable blood volume in 24 hours recommend that no more than 1-5% of total blood volume (75-80 ml/kg for older children) be obtained. Applying the average weight of a 2 year old toddler =12 kg, the allowable blood volume to be drawn in 24 hours at 1-5% of the total blood volume is 9.6 - 48 mL .

For minors, caregivers will provide informed consent. Documented assent for children of 12 to 16 years of age will be required for their participation.

Exclusion Criteria:

  • Subjects who are felt to be in critical condition (based on clinician assessment or the presence of any general signs of critical illness as defined by WHO guidelines (for children: extensive vomiting, active seizure or recent history of seizures, altered mentation, inability to feed, or any of the severe IMNCI classifications; for adults: impending airway obstruction, central cyanosis, severe respiratory distress, feeble pulse, active seizure or recent history of seizures, or unconsciousness) because the target population for the study is non-severe febrile subjects.
  • Subjects can only be enrolled once into the study.
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
2,000 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Malawi febrile patients

    Children and adults with fever presenting at the outpatient department

    Diagnostic Test: Biomarker assay

  • Brazil febrile patients

    Children and adults with fever presenting at the outpatient department

    Diagnostic Test: Biomarker assay

  • Gabon febrile patients

    Children with fever or with a recent history of fever presenting at the outpatient department

    Diagnostic Test: Biomarker assay

Interventions

  • Diagnostic testBiomarker assay

    There is no intervention on the patients but biomarker assays are being evaluated for their performance to distinguish bacterial infection from non-bacterial infections in febrile patients

05

What researchers measure

Primary outcomes

  1. Diagnostic sensitivity and specificity to determine bacterial infections compared to clinical and microbiological results aggregated in a study database.

    Microbiological testing (blood culture positive/negative, malaria pos/neg, S. Tyhpi RDT pos/neg) and clinical assessments of symptoms (respiratory, gastro, no foci) will be recorded and reviewed by a clinical panel upon completion of the study to assign a final category (bacterial or non-bacterial). These categories are used in the evaluation of the biomarker assays to evaluate their performance in differentiating bacterial from non-bacterial infections. Where applicable, the same categories will be used to determine the area under the curve by employing receiver operator characteristics (ROC) analysis of quantitative markers.

    Time frame: 1year

06

Study locations

3 sites
  • Instituto Nacional de Infectologia Evandro Chagas - Fiocruz (INIEC)
    Rio de Janeiro, Brazil
  • CERMEL
    Lambaréné, Gabon
  • Karonga Prevention Study
    Chilumba, Karonga District, Malawi
07

References and documents

Individual participant data

Plan to share: Yes — As appropriate data will be made available to the scientific community and/or commercial partners to support product development activities.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03047642
Lead sponsor
Foundation for Innovative New Diagnostics, Switzerland
Collaborators
Malawi Epidemiology and Intervention Research Unit, Instituto Nacional de Infectologia Evandro Chagas, Centre de Recherche Médicale de Lambaréné
Responsible party
Sponsor
First posted
Feb 9, 2017
Start date
Apr 27, 2017
Primary completion
Oct 27, 2018
Completion
Nov 27, 2019
Last update
Feb 16, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion